Stockscreener 앱 받기
3.01
5.05%
-0.16
시간 외 거래:
3.02
0.01
+0.33%
전일 마감가:
$3.17
열려 있는:
$3.18
하루 거래량:
2.81M
Relative Volume:
1.67
시가총액:
$343.28M
수익:
$884.00K
순이익/손실:
$-103.64M
주가수익비율:
-2.1586
EPS:
-1.3944
순현금흐름:
$-95.45M
1주 성능:
-17.08%
1개월 성능:
+2.03%
6개월 성능:
+5.99%
1년 성능:
-26.76%
1일 변동 폭
$2.895
$3.19
1주일 범위
$2.895
$3.77
52주 변동 폭
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.01 | 343.28M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | Piper Sandler | Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus
Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times
Perspective Therapeutics taps Merck KGaA oncology chief in planned science shift - Stock Titan
Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr
Perspective Therapeutics (CATX) Proxy filing Summary - Quartr
Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr
Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor ConfidenceEarnings Revision Downgrade - dars.gov.et
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Enliven Therapeutics Surges on Promising Leukemia Drug Trial ResultsEarnings Outlook Update - newsline.com
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Perspective Therapeutics Inc 주식 (CATX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Williamson Robert F III | Director |
Nov 12 '25 |
Buy |
2.10 |
9,498 |
19,946 |
9,864 |
2.36%
자본화:
|
볼륨(24시간):